UNSPSC 51332817: Promazine

This classification denotes a phenothiazine and antipsychotic agent with the molecular formula C17H20N2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O9M39HTM5W, chemically known as 10h-phenothiazine-10-propanamine, n,n-dimethyl-, monohydrochloride but generally known as promazine, which bears US NIH Compound Identifier 4926. European Medicines Agency schedules Promazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10085MIG.

UNSPSC 51332817 Promazine is a Commodity code for pharmaceutical products, but the recent state and local activity tagged under it reflects procurement of naloxone and drug deactivation systems rather than promazine specifically. State and local governments use this code tier to acquire emergency response medications and harm-reduction equipment. Issuing bodies include county health departments and community health agencies that support public health and opioid-response initiatives. Vendors must meet standard compliance requirements including drug-free workplace certification, E-Verify enrollment, appropriate insurance coverage, and federal environmental regulations when federal funding is involved.

Seminole County, Florida posted the most recent opportunity under this code: IFB 60459723LAS, issued June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford. The IFB response deadline was July 26, 2023, at 2:00 pm; vendors submit bids electronically and must include all shipping and delivery costs in their proposals. The initial contract term is two years with an optional one-year renewal on a fixed-fee basis. The procurement carries potential FEMA funding, which introduces additional federal compliance obligations. This represents the sole recent opportunity visible under the code; activity appears sparse, and the code's nominal scope (promazine) diverges from what is actually being procured (opioid-response and harm-reduction products), suggesting either a classification mismatch or limited state and local use of this particular code designation.